300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
.2CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Annual Report to Security Holders
Boston Scientific Enters $3 Billion Revolving Credit Agreement
Elects Cathy Smith and Christophe Weber to Board of Directors
Director Departure - Yoshiaki Fujimori Not Standing for Re-Election
Announces Results for Fourth Quarter and Full Year 2025
Boston Scientific Enters Merger Agreement with Penumbra, Inc.
Announces Agreement to Acquire Penumbra, Inc.
FY 2024
Q3
Q2
Q1
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
S-4/A
Prospectus Filed Pursuant to Rule 425
S-4
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Specialized Disclosure Report
Free Writing Prospectus